Savara, Inc. (SVRA)
| Market Cap | 130.95M |
| Revenue (ttm) | 1,000 |
| Net Income (ttm) | -45.45M |
| Shares Out | 113.87M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 356,569 |
| Open | 1.21 |
| Previous Close | 1.22 |
| Day's Range | 1.13 - 1.22 |
| 52-Week Range | 1.03 - 3.58 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+334.8%) |
| Earnings Date | n/a |
About SVRA
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Savara stock is "Strong Buy." The 12-month stock price forecast is 5.00, which is an increase of 334.78% from the latest price.
News
Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new em...
Savara to Participate in Two Upcoming Investor Healthcare Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...
Savara Reports Third Quarter 2021 Financial Results and Provides Business Update
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter ending...
Savara to Present at the Jefferies London Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...
Savara to Present at the Inaugural Piper Sandler Lung Day
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in ...
Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new emp...
Savara Reports Second Quarter 2021 Financial Results and Provides Business Update
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the second quarter endin...
3 Net Current Asset Value Stock Picks
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can make huge margins of return out of these stocks after the market h...
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study
Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the ...
Implied Volatility Surging for Savara (SVRA) Stock Options
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Savara to Present at the Jefferies Virtual Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at ...
Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at ...
Savara Reports First Quarter 2021 Financial Results and Provides Business Update
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the first quarter ending...
Penny Stocks To Buy According To Analysts With Price Targets Up to 341%
Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks ...
7 Penny Stocks with Interesting Catalysts
While penny stocks are always incredibly risky ventures, these publicly traded companies offer interesting catalysts to consider. The post 7 Penny Stocks with Interesting Catalysts appeared first on Inv...
7 Reddit Penny Stocks Seeing the Most Chatter Today
Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today ...
Do Options Traders Know Something About Savara (SVRA) Stock We Don't?
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Savara Stock Rallies: Technical Analysis Levels
Savara Inc. (NASDAQ:SVRA) shares rallied Tuesday after Piper Sandler initiated coverage of the stock with an Overweight rating and $7 price target.
Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters' Option
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of i...
Savara Announces Pricing of Public Offering of Common Stock
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a p...
Savara Announces Proposed Public Offering of Common Stock
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in...